Comparative results of treatment for chronic hepatitis C in HIV-infected patients receiving and not receiving highly active antiretroviral therapy

The paper presents the comparative results of treatment for chronic hepatitis C in HIV-infected patients in two groups: those who receive and do not receive highly active antiretroviral therapy (HAART). The findings indicated that the efficiency of therapy for hepatitis was comparable in both groups: the proportions of patients with a steady-state virological response who received and did not receive HAART were 34.1 and 40.9%, respectively. Some adverse reactions significantly differed in their frequency in both groups. Nevertheless, their severity was that which did not require hepatitis therapy discontinuance.